How a weight loss drug's approval could affect insurance premiums

Nov 10, 2023
The FDA's approval of Eli Lilly's Zepbound could signal more insurers paying for the use of such drugs. Demand is great so the costs could be big and push up premiums.
Eli Lilly’s newly FDA-approved weight loss drug, Zepbound, is priced roughly 21% lower than competitor Novo Nordisk’s Wegovy.
Eli Lilly